| pubmed-article:15584487 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:15584487 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:15584487 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:15584487 | lifeskim:mentions | umls-concept:C0751967 | lld:lifeskim |
| pubmed-article:15584487 | lifeskim:mentions | umls-concept:C1332709 | lld:lifeskim |
| pubmed-article:15584487 | lifeskim:mentions | umls-concept:C1704259 | lld:lifeskim |
| pubmed-article:15584487 | lifeskim:mentions | umls-concept:C1819447 | lld:lifeskim |
| pubmed-article:15584487 | lifeskim:mentions | umls-concept:C1705987 | lld:lifeskim |
| pubmed-article:15584487 | pubmed:issue | 6 | lld:pubmed |
| pubmed-article:15584487 | pubmed:dateCreated | 2004-12-8 | lld:pubmed |
| pubmed-article:15584487 | pubmed:abstractText | Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system probably mediated by Th1 lymphocytes. IFN-beta is an established therapy for relapsing MS patients, although the mechanisms underlying its efficacy are yet to be well characterized. We determined IL-2 production, CD25 expression and T-cell proliferation from relapsing-remitting MS patients before and three months after starting therapy. A decrease in the percentage of CD80-induced IL-2-producing cells was observed after in vivo IFN-beta treatment. These data support that one of the immunomodulatory effects of IFN-beta treatment in MS may be a limitation of the autoimmune response modifying the CD80:CD28/CTLA-4 pathway. | lld:pubmed |
| pubmed-article:15584487 | pubmed:language | eng | lld:pubmed |
| pubmed-article:15584487 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15584487 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:15584487 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15584487 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15584487 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15584487 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15584487 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15584487 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15584487 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15584487 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15584487 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15584487 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:15584487 | pubmed:month | Dec | lld:pubmed |
| pubmed-article:15584487 | pubmed:issn | 1352-4585 | lld:pubmed |
| pubmed-article:15584487 | pubmed:author | pubmed-author:RíoJJ | lld:pubmed |
| pubmed-article:15584487 | pubmed:author | pubmed-author:RuggieroGG | lld:pubmed |
| pubmed-article:15584487 | pubmed:author | pubmed-author:BrievaLL | lld:pubmed |
| pubmed-article:15584487 | pubmed:author | pubmed-author:MontalbanXX | lld:pubmed |
| pubmed-article:15584487 | pubmed:author | pubmed-author:Martínez-Cáce... | lld:pubmed |
| pubmed-article:15584487 | pubmed:author | pubmed-author:EspejoCC | lld:pubmed |
| pubmed-article:15584487 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:15584487 | pubmed:volume | 10 | lld:pubmed |
| pubmed-article:15584487 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:15584487 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:15584487 | pubmed:pagination | 630-5 | lld:pubmed |
| pubmed-article:15584487 | pubmed:dateRevised | 2011-11-17 | lld:pubmed |
| pubmed-article:15584487 | pubmed:meshHeading | pubmed-meshheading:15584487... | lld:pubmed |
| pubmed-article:15584487 | pubmed:meshHeading | pubmed-meshheading:15584487... | lld:pubmed |
| pubmed-article:15584487 | pubmed:meshHeading | pubmed-meshheading:15584487... | lld:pubmed |
| pubmed-article:15584487 | pubmed:meshHeading | pubmed-meshheading:15584487... | lld:pubmed |
| pubmed-article:15584487 | pubmed:meshHeading | pubmed-meshheading:15584487... | lld:pubmed |
| pubmed-article:15584487 | pubmed:meshHeading | pubmed-meshheading:15584487... | lld:pubmed |
| pubmed-article:15584487 | pubmed:meshHeading | pubmed-meshheading:15584487... | lld:pubmed |
| pubmed-article:15584487 | pubmed:meshHeading | pubmed-meshheading:15584487... | lld:pubmed |
| pubmed-article:15584487 | pubmed:meshHeading | pubmed-meshheading:15584487... | lld:pubmed |
| pubmed-article:15584487 | pubmed:meshHeading | pubmed-meshheading:15584487... | lld:pubmed |
| pubmed-article:15584487 | pubmed:meshHeading | pubmed-meshheading:15584487... | lld:pubmed |
| pubmed-article:15584487 | pubmed:meshHeading | pubmed-meshheading:15584487... | lld:pubmed |
| pubmed-article:15584487 | pubmed:meshHeading | pubmed-meshheading:15584487... | lld:pubmed |
| pubmed-article:15584487 | pubmed:meshHeading | pubmed-meshheading:15584487... | lld:pubmed |
| pubmed-article:15584487 | pubmed:meshHeading | pubmed-meshheading:15584487... | lld:pubmed |
| pubmed-article:15584487 | pubmed:meshHeading | pubmed-meshheading:15584487... | lld:pubmed |
| pubmed-article:15584487 | pubmed:meshHeading | pubmed-meshheading:15584487... | lld:pubmed |
| pubmed-article:15584487 | pubmed:meshHeading | pubmed-meshheading:15584487... | lld:pubmed |
| pubmed-article:15584487 | pubmed:meshHeading | pubmed-meshheading:15584487... | lld:pubmed |
| pubmed-article:15584487 | pubmed:meshHeading | pubmed-meshheading:15584487... | lld:pubmed |
| pubmed-article:15584487 | pubmed:year | 2004 | lld:pubmed |
| pubmed-article:15584487 | pubmed:articleTitle | IFN-beta treatment modulates the CD28/CTLA-4-mediated pathway for IL-2 production in patients with relapsing-remitting multiple sclerosis. | lld:pubmed |
| pubmed-article:15584487 | pubmed:affiliation | Unitat de Neuroimmunologia Clínica, Hospital Universitari Vall d'Hebron, Barcelona, Spain. cespejo@vhebron.net | lld:pubmed |
| pubmed-article:15584487 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:15584487 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:15584487 | pubmed:publicationType | Controlled Clinical Trial | lld:pubmed |
| pubmed-article:15584487 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15584487 | lld:pubmed |
